{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39","upperLimit":"56","value":"47"}]}],"title":"1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46","upperLimit":"63","value":"54"}]}],"title":"2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"}],"units":"Participants"}],"description":"Incidence and severity of chronic GVHD will be scored according to the BMT clinical trials network Manual of Procedures.","dispersionType":"95% Confidence Interval","groups":[{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients","id":"OG000","title":"Auto-Allo Standard Risk"}],"paramType":"NUMBER","populationDescription":"GVHD was only assessed on the Auto-Allo arm for standard risk patients that completed second transplant","reportingStatus":"POSTED","timeFrame":"Years 1 and 2","title":"Incidences of Chronic GVHD","type":"SECONDARY","unitOfMeasure":"percentage of patients"}